GlassScriptPhysician profile
Amanda Brink
NPI 1568871101
$8,445.29
in general payments reported to CMS, 2019-2025
30 companies · $1,455 in 2025
The $1,455 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,614 · 2023: $2,487 · 2024: $2,890 · 2025: $1,455.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,740 · Consulting Fee: $1,849 · Travel and Lodging: $1,151 · Honoraria: $58.00 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,739.65 |
| Consulting Fee | $1,849.00 |
| Travel and Lodging | $1,150.88 |
| Honoraria | $58.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,805.73 | 2024-2025 | Imdelltra (Amg 757) |
| Astrazeneca Pharmaceuticals LP | $1,429.94 | 2023 | |
| G1 Therapeutics, INC. | $1,365.40 | 2022 | |
| Abbvie INC. | $529.61 | 2023 | |
| Gilead Sciences, INC. | $410.92 | 2024-2025 | Epclusa, Vemlidy |
| Xeris Pharmaceuticals, INC. | $229.27 | 2024-2025 | Gvoke Hypopen, Recorlev |
| Corcept Therapeutics | $206.12 | 2025 | Korlym |
| Janssen Biotech, INC. | $163.73 | 2025 | Rybrevant, Carvykti |
| Spectrum Pharmaceuticals INC. | $162.42 | 2024 | Rolvedon |
| Abbott Laboratories | $145.90 | 2025 | Proclaim |
| Inspire Medical Systems, INC. | $132.34 | 2024 | Inspire |
| Pharmacosmos Therapeutics INC. | $125.00 | 2025 | Cosela |
| Seagen INC. | $125.00 | 2023 | Adcetris |
| Incyte Corporation | $124.96 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $123.40 | 2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $123.16 | 2024 | |
| Genzyme Corporation | $121.52 | 2024 | |
| Genentech USA, INC. | $120.88 | 2023 | |
| Apellis Pharmaceuticals, INC. | $119.53 | 2024 | Empaveli |
| Ucb, INC. | $116.58 | 2024 | Briviact |
| Puma Biotechnology, INC. | $112.90 | 2023 | Nerlynx |
| Bayer Healthcare Pharmaceuticals INC. | $100.29 | 2025 | |
| Daiichi Sankyo INC. | $100.00 | 2023 | |
| Vertex Pharmaceuticals Incorporated | $96.19 | 2025 | |
| Becton, Dickinson and Company | $92.00 | 2025 | Introducer Needle |
| Eisai INC. | $84.38 | 2025 | |
| Biogen, INC. | $68.61 | 2023 | |
| Tempus Ai, INC | $63.55 | 2025 | Xt Cdx |
| Tersera Therapeutics LLC | $25.97 | 2025 | Zoladex |
| Emd Serono, INC. | $19.99 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Brink listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.